CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04611100
NCT04611100N/ACompleted

Efficacy of Intraductal Radiofrequency Ablation in Combination With Metallic Biliary Stenting in Advanced Hilar Cholangiocarcinoma

Department of Medical Services Ministry of Public Health of Thailand·interventional·Posted Nov 2, 2020·Updated Mar 23, 2022

In Brief

A clinical study evaluating ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) for Hilar Cholangiocarcinoma and Biliary Obstruction. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The study aim to evaluate the efficacy of intraductal radiofrequency ablation for unresetable hilar cholangiocarcinoma in addition to biliary stenting. The patient would be randomized into 1:1 ratio of conventional group who received biliary stenting alone, and RFA group who receive intraductal RFA before biliary stenting. Immediate complications as well as long term stent patency and patient survival would be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesThailand
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 2, 2020
Enrollment StartApr 1, 2020
Primary CompletionDec 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.7 years ago

Interventions

ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)device

Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent